Loading patent…
AssigneeKorea Atomic Energy Research Institute
InventorsIn-Gyu Kim, Soo Im Choi, Byung-Chul Shin
Estimating the term…
The present invention relates to a pharmaceutical composition or an anticancer agent for preventing and treating non-small cell lung cancer, containing a substance for regulating the expression or activity of transmembrane 4 L six family member 4 (TM4SF4). More specifically, the present invention relates to a use of a substance for regulating the expression or activity of TM4SF4 as an anticancer drug or an anticancer agent with respect to non-small cell lung cancer, wherein it was ascertained that it is possible to decrease the growth, metastasis, and infiltration of adenocarcinoma cells and radioresistance by decreasing the expression of TM4SF4 in adenocarcinoma among non-small cell lung cancers and to decrease the growth, metastasis, and infiltration of the cells and radioresistance by increasing the expression of TM4SF4 in other non-small cell lung cancers except adenocarcinoma.
1-13. (canceled)
A method for screening an anticancer drug or an enhancer candidate to increase radiosensitivity of non-small cell lung cancer adenocarcinoma cells or non-adenocarcinoma non-small cell lung cancer cells, comprising the following steps:
(canceled)
19-28. (canceled)
A method for treating non-small cell lung adenocarcinoma cancers or increasing radiosensitivity of non-small cell lung cancer adenocarcinoma cells, comprising administering a pharmaceutically effective dose of an inhibitor of the expression or activity of TM4SF4 (transmembrane 4 L six family member 4) to a subject having non-small cell lung adenocarcinoma, wherein the inhibitor of the expression of TM4SF4 is the antisense nucleotide or the small interfering RNA binding complementarily to TM4SF4 mRNA, or antibodies complementarily binding to TM4SF4 protein.
A method for treating non-adenocarcinoma non-small cell lung cancers or increasing radiosensitivity of non-adenocarcinoma non-small cell lung cancers, comprising administering a pharmaceutically effective dose of an expression vector harboring a gene encoding TM4SF4 protein to a subject having non-adenocarcinoma non-small cell lung cancer.
Dependencies are inferred from the claim text.